Amarantus Bioscience Holdings Inc (AMBS)

[JPetroInc]

so will Jeffrey Stephens V.P. of Global Acquisitions of International Infusion provide clarification as to why AMDX has failed thus far to live up to his below claims made public on 08/01/2015:

"Sounds like a lot?!? Well, Gerald was just warming up. He recently has created Amarantus DX. They boost that this will be the most robust neurological diagnostic line of assets ever assembled inside of one company. Many ways to play this and it will be interesting to see if he spins this out or keeps it in house. But you can beat that the company is working on it. With acceptance of data into major journals, the word about MS Precise is getting out there. The result is that Amarantus was able to attract a top advisory board with high levels of industry experience to the company. From Dr. Goix to Dr. Wand to Mr. Guillen their expertise and connections reaches through the heart of the diagnostic community. Raising over $70mm in equity capital, Dr. Giox also developed revenues of over $60mm annually. Why would they join? One would speculate that they see the potential of the assets.

On the doorstep of commercialization, MS Precise is ready to run through. Yes, it will take a few years to maximize revenue but the process is started and there are plans to have this hit commercialization soon. The recent journal news shows that the medical community is taking note and will give doctors the confidence they need to one day use the diagnostic. Lympro has been constantly criticized on the message boards and shareholders seem very confused on this asset. The recent data released has shown consistency and if this consistency is further supported by PET imaging then it could be special. The first customer has been brought in and if a heavy hitter comes in and uses Lympro then we can expect others will follow.
"